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ABSTRACT 
Objective. In recent years, large-scale genetic studies have identified several loci 
associated with specific disorders involving uveitis, such as Behçet’s disease, Vogt-
Koyanagi-Harada syndrome, sarcoidosis and birdshot chorioretinopathy (BSCR). The 
aim of the present study was to identify new genetic risk factors associated with non-
infectious uveitis by performing a dense genotyping of immune-related loci using the 
Immunochip platform. 
Design. Case/control study 
Participants.We analysed a total of 613 cases and 3,693 unaffected controls from three 
independent case/control sets of European ancestry. Only patients diagnosed with non-
infectious and non-anterior uveitis and without systemic features were selected for the 
study.  
Methods. Patients were genotyped using the Immunochip array. To perform a more 
comprehensive analysis of the human leucocyte antigen (HLA) region, single-nucleotide 
polymorphisms (SNPs), classical HLA alleles (at two- and four-digit resolution) and 
polymorphic amino acid variants were obtained via imputation. In each cohort, genetic 
variants which passed quality control filters were tested for association by logistic 
regression. Subsequently, a meta-analysis combining the three case/control sets was 
conducted by the inverse variance method. 
Main Outcome Measures. Association of genetic variants located in immune-related loci 
with the susceptibility to non-anterior non-infectious uveitis. 
Results.The highest peak belonged to the HLA region. A more detailed analysis of this 
signal evidenced a strong association between the classical allele HLA-A*2902 and 
BSCR (p=3.21E-35, OR=50.95). An omnibus test on polymorphic amino acid positions 
yielded HLA-A 62 and 63 as relevant positions for this disease. In patients with 
intermediate and posterior uveitis, the strongest associations belonged to the rs7197 
polymorphism, within the HLA-DRA gene (p=2.07E-11, OR=1.99), and the HLA-DR15 
haplotype (DRB1*1501: p=1.16E-10, OR=2.08; DQA1*0102: p=4.37E-09, OR=1.77; 
DQB1*0602 alleles: p=7.26E-10, OR=2.02). Outside the HLA region, the MAP4K4/IL1R2 
locus reached statistical significance (rs7608679: p=8.38E-07, OR=1.42). In addition, 
suggestive associations were found at five other genetic regions. 
Conclusions. Through an Immunochip approach, we have further interrogated the 
association between the HLA region and non-infectious intermediate, posterior and 
panuveitis. In addition, we have identified a new susceptibility factor and proposed 
additional risk loci with putative roles in this condition.  
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INTRODUCTION 
Non-infectious uveitis is an immune-mediated condition characterized by intraocular 
inflammation, which mainly affects the uveal tract but also adjacent structures,including 
the retina and its vessels, the vitreous and the optic nerve1. Non-infectious uveitis 
comprises a heterogeneous group of disorders diagnosed according to their clinical 
phenotype that may be confined to the eye or associated with systemic disorders. Based 
on the location of the inflammation, uveitis can be classified as anterior, posterior, 
intermediate and panuveitis2. While anterior uveitis has the best visual prognosis, non-
anterior uveitis patients have a greater risk of permanent vision loss, and often require 
systemic immunosuppressive therapy3. Nowadays, non-infectious uveitis is considered 
a major cause of visual impairment in the working age population, which is responsible 
for up to 10% of cases of blindness in developed countries4.   
In recent years, there have been substantial advances in our understanding of the 
pathogenic mechanisms leading to non-infectious uveitis5. Although the precise 
pathogenesis remains unclear, accumulating evidence points to the interplay between a 
complex genetic background together with a deregulated immune response in its 
development. In this regard, large-scale genetic studies have been performed in several 
systemic diseases associated with uveitis, including Behçet’s disease6-12, Vogt-
Koyanagi-Harada syndrome (VKH)13, and sarcoidosis14-19, as well as in inflammatory 
disorders confined to the eye, such as birdshot chorioretinopathy (BSCR)20. This 
approach has identified several genetic risk loci, mainly immune/inflammatory response 
genes and genes of the human leukocyte antigen (HLA) region, many of which (such as 
IL23R, STAT4 or ERAP1/ERAP2) are shared by the different uveitic syndromes as well 
as by other immune-mediated diseases. 
All published large-scale genotyping scans to date have investigated specific systemic 
syndromes without considering the shared genetic determinants that might predispose 
to uveitis per se, independent of the clinical diagnosis. Therefore, to further discover the 
genetic component of non-infectious uveitis, we decided to perform a dense genotyping 
of immune-related loci using the Immunochip platform in patients with non-infectious 
non-anterior uveitis without systemic features. 
 
 
METHODS 
Study population 
Three independent case/control sets of European ancestry, 360 cases and 1517 
unaffected controls from Spain, 142 cases and 1173 unaffected controls from the 
Netherlands and 111 cases and 1003 unaffected controls from the United Kingdom (UK) 
were included in the study. Spanish and British cohorts have been used and 
characterised in previous association studies 21, 22. Only patients diagnosed with non-
infectious and non-anterior uveitis (the most severe form of uveitis) were selected. In 
addition, to avoid the identification of signals associated with other clinical 
manifestations, the uveitis entities related to systemic diseases, except VKH, were 
excluded from the analysis. VKH was included considering that uveitis appears in 100% 
of the patients, with or without systemic involvement. Non-anterior uveitis patients were 
classified according to the anatomical location of the inflammation as posterior uveitis, 
intermediate uveitis and panuveitis. Informed written consent from all participants and 
approval from the local ethical committees were obtained in accordance with the tenets 
of the Declaration of Helsinki. Supplementary Table 1 shows the main characteristics 
of the case cohorts included in the study. 
 
Genotyping 
Genomic DNA was extracted from saliva samples or whole blood by standard methods. 
The genotyping was performed at a single center on the Illumina iScan system with the 
Immunochip platform, which allows a dense analysis of single-nucleotide polymorphisms 
(SNPs), rare variants, and insertion/deletion (indel) polymorphisms. All the Spanish 
samples (cases and controls) as well as unaffected subjects from the Netherlands and 
the UK were genotyped using the HumanImmunov1.0 BeadChip (196,524 genetic 
markers), whereas uveitis samples from the Netherlands and the UK were genotyped 
using the Infinium ImmunoArray-24 v2.0 BeadChip (253,702 genetic markers). Genetic 
variants included in both platforms overlap by 80%. 
 Quality control and imputation 
Data quality control was performed for each sample set separately prior to imputation. 
SNPs and subjects with successful call rates lower than 98% and 95%, respectively, 
were removed using PLINK v.1.723. SNPs with minor allele frequencies lower than 0.01 
and those that were not in Hardy-Weinberg equilibrium (HWE; p < 0.001) were also 
excluded. In addition, one subject per duplicate pair and per pair of first-degree relatives 
was also removed via the Genome function in PLINK v.1.7 with a Pi-HAT threshold of 
0.4. 
IMPUTE v.2. software was used to perform imputations24, with The 1000 Genomes 
Phase 3 as reference panel25. Imputed data were subsequently subjected to stringent 
quality filters inPLINK v.1.7; i.e., individuals who generated genotypes <98% were 
removed, and SNPs with call rates <95% and those that deviated from HWE (p < 0.001) 
were also discarded. Principal-component (PC) analyses were performed to identify and 
exclude outliers based on their ethnicity in PLINK v.1.7 and the gcta64 and R-base under 
GNU Public license v.2. With this software, we calculated the ten first PCs using the 
markers informative of ancestry that were included in the Immunochip. Those subjects 
showing more than four standard deviations from the cluster centroids were excluded as 
outliers. 
 
Imputation of the HLA region 
HLA imputation was performed for 8,961 common SNPs, representing classical HLA 
alleles, amino acids, and SNPs, across the extended major histocompatibility complex 
region. We used the SNP2HLA method with the Beagle software package26 and a 
reference panel collected by the Type 1 Diabetes Genetics Consortium comprised of 
5,225 individuals of European origin27. 
 
Statistical analysis 
The statistical analyses were performed with PLINK v.1.7 and R. First, each case/control 
cohort was independently analyzed by logistic regression on the best-guess genotypes 
(>0.9 probability) assuming an additive model with the first ten PCs as covariates. 
Subsequently, the three case/control sets were combined by inverse variance weighted 
fixed effects meta-analysis. Heterogeneity of the ORs across studies was estimated by 
Cochran’s Q and I2 tests. The presence of independent effects was examined using a 
stepwise logistic regression by conditioning on a lead SNP, the first ten PCs and the 
country of origin as covariates. 
For the HLA region, an omnibus association test28 was also performed to determine the 
influence of the polymorphic amino acid positions on disease susceptibility. For each 
amino acid position, a null generalized linear model, including the first ten PCs and the 
country of origin as covariates, was built and compared with an alternative model, 
including the same variables and all the possible alleles in the analyzed amino acid 
positions, by a likelihood ratio test (LRT). Additionally, we also conducted conditional 
analyses controlling by the most associated positions by including them as covariates in 
the models.  
The Manhattan plots were obtained with an in-house modification of the R script written 
by Stephen Turner. Results of the imputed regions were plotted using the on line tool 
LocusZoom v.1.133 (http://locuszoom.sph.umich.edu/locuszoom/). 
Contrary to genome-wide association studies (GWASs), the Immunochip platform is not 
based on SNPs tagging the whole genome, but on a fine mapping of candidate disease-
associated loci. Thus, it has been proposed that, since tests are correlated, using the 
strict genome-wide significance threshold (5x10-8) could be an over correction29. Taking 
this into account, we estimated the appropriate Bonferroni-based statistical threshold for 
our study using the Genetic type 1 Error Calculator (GEC) software30, which calculates 
the effective number of independent tests. A significant threshold of 1.14x10-6 was 
obtained and, therefore, p-values below this threshold were considered as statistically 
significant. A suggestive tier of association (2.29x10-5) was also calculated using this 
software. 
The statistical power of the study was estimated by using CaTS Power Calculator for 
Genetic Studies31, setting the significance level at 1.14x10-6 (Supplementary Table 2). 
 
Functional annotation 
After meta-analysis, the associated SNPs, as well as those in high linkage disequilibirum 
(LD) (r2 > 0.8) with them (using the European populations of the 1000 Genomes Project 
Phase III data), were interrogated for potential regulatory function. The HaploReg v4.1 
database32 was used to evaluate whether they were located within regulatory DNA 
elements, including regions of DNAase hypersensitivity, binding sites of transcription 
factors or chromatin marks. Their effect on gene expression was also explored using 
HaploReg v4.1 by means of in silico expression quantitative trait locus (eQTL) analysis. 
RESULTS 
Following SNP and sample quality control, we analysed a total of 187,951 genetic 
variants in 579 cases of non-infectious and non-anterior uveitis and 3,676 controls of 
European ancestry. 
As shown in Figure 1, two signals reached the established significance threshold 
(1.14x10-6) in the inverse-variance meta-analysis including the three cohorts. These 
peaks lied within the HLA region and the chromosomal region 2q11.2.  
 
HLA associations 
After imputation, a high association peak was observed within the HLA class I region 
(Supplementary Figure 1). Specifically, the top associated signal belonged to the 
classical allele HLA-A*2902 (p=1.04E-16, OR=2.41). The strong association between 
this HLA allele and BSCR is well established 33, and many patients with this condition 
(n=78/613) were included in our analysis. Therefore, in order to determine whether this 
signal was due to a strong association with the BSCR subgroup of patients, we decided 
to further stratify our analyses of the HLA region by considering the BSCR patients on 
one hand, and the remaining uveitis patients on the other hand. 
HLA analyses in the subgroup of patients with BSRC. When BSRC patients (n=78) 
were independently analyzed, a stronger association between the classical allele HLA-
A*2902 and this disease was evident (p=3.21E-35, OR=50.95) (Figure 2 and 
Supplementary Table 3). Although several SNPs, linked to this classical allele, also 
showed strong associations, HLA-A*2902 had the greatest effect size (Supplementary 
Table 3). Signals within the HLA-B, -C and class II regions were also observed; however, 
no independent secondary effects were found after controlling for the effect of HLA-
A*2902 (Figure 2 and Supplementary Table 3). 
Subsequently, we examined whether a specific amino acid position could be responsible 
for the association observed for this classical allele by means of an omnibus test 
(Supplementary Figure 2 and Supplementary Table 4). The most relevant amino acid 
positions for disease risk were the positions 63 and 62 of the HLA-A molecule 
(PLRT=1.44E-58 and PLRT=3.99E-57, respectively). After performing the omnibus test 
conditioning on either of these two polymorphic positions, none of the other signals 
remained significant (Supplementary Figure 2 and Supplementary Table 4).  
Table 1 shows the most associated amino acid residues in both positions, Leu in position 
62 and Gln in position 63 (p=5.33E-35, OR=49.48), which are in complete LD. Both 
residues showed statistically nearly indistinguishable effects compared to the classical 
allele HLA-A*2902 (OR=50.95). When we performed a logistic regression analysis 
adjusting for HLA-A*2902, the association of Leu-62/Gln-63 with BSCR was lost 
(p=0.111). Similarly, after controlling for either of these two residues, the association 
between HLA-A*2902 and BSCR also lost its statistical significance (p=0.294) (Figure 2 
andSupplementary Table 3). 
HLA analyses in non-infectious non-anterior uveitis patients excluding BSCR. 
Subsequently, we considered the remaining uveitis patients who did not have BSRC 
(Supplementary Figure 3and Supplementary Table 5). After excluding patients with 
BSCR, no signals in the class I region were observed; thus indicating that the association 
between HLA-A*2902 and uveitis observed in our initial analysis was due to the strong 
association of this allele with BSCR. However, a peak within the HLA class II region was 
evident, with a set of SNPs, located within the HLA-DRA gene and in close LD, showing 
the strongest signal (highest hit rs3129888: p=6.33E-09, OR=1.65) (Supplementary 
Figure 3 and Supplementary Table 5). Additionally, these SNPs were strongly linked 
to the classical alleles forming the HLA-DR15 haplotype, DRB1*1501, DQA1*0102 and 
DQB1*0602, which also appeared to be associated with disease (p=3.23E-08, 
OR=1.72;p=6.86E-08, OR=1.57; and p=3.03E-08, OR=1.73, respectively).  
Since an association between the DR15 haplotype and idiopathic intermediate uveitis 
has been reported previously34, 35, we reanalysed the HLA region stratifying patients 
according to the anatomical location of their inflammation (Supplementary Figure 4). 
In the group of patients with intermediate uveitis, a peak within the HLA class II region 
was observed, although no significant associations were found. The largest signals 
corresponded to the set of SNPs located within HLA-DRA (highest hit rs7197: p=8.91E-
05, OR=1.78). As previously described, the classical alleles DRB1*1501, DQA1*0102 
and DQB1*0602, also appeared between the most significant variants (p=8.92-04, 
OR=1.72; p=9.26E-04, OR=1.58; and p=2.06E-03, OR=1.67, respectively). 
Interestingly, when we analyzed the group of patients with posterior uveitis, a similar 
pattern was evident. Again, the highest signals arose from DRA polymorphisms (highest 
hit rs3135388: p=2.06E-09, OR=2.38) and the DRB1*1501 (p=2.93E-09, OR=2.36) and 
DQB1*0602 (p=8.08E-09, OR=2.30) alleles. Indeed, in this subgroup of patients, these 
class II signals reached the genome-wide significance level.  
Finally, when we analyzed the last subgroup of uveitis patients, those with panuveitis, 
we did not observe any peak within the HLA region. 
HLA analyses in patients with intermediate and posterior uveitis. Since a similar 
pattern of association between HLA-DR and -DQ alleles and either intermediate and 
posterior uveitis was observed, we next combined both subgroup of patients to better 
define the association between this HLA region and these clinical phenotypes. As 
expected, the strongest signals corresponded to HLA-DRA variants (highest hit rs7197: 
p=2.07E-11, OR=1.99) and the HLA-DRB1*1501 classical allele (p=1.16E-10, OR=2.08) 
(Figure 3 and Supplementary Table 6). We next carried out a step-wise conditional 
logistic regression analysis to identify HLA alleles that independently influenced the 
susceptibility. No additional independent associations were observed after conditioning 
on either of the top signals, rs7197 or DRB1*1501 (Figure 3 and Supplementary Table 
6). 
After performing the omnibus test, the positions 133 and 142 of the HLA-DRβ1 molecule 
(which are completely linked) appeared to be the most associated with posterior and 
intermediate uveitis (PLRT=1.64E-09) (Supplementary Figure 5 andSupplementary 
Table 7). All the remaining associated positions were explained by linkage to HLA-DRβ1 
133/142 after performing the conditioned omnibus test (Supplementary Figure 5 
andSupplementary Table 7). 
Table 2 shows the most associated amino acid residues with intermediate and 
posterior uveitis. Positions 133 and 142 were biallelic in the analysed cohort, with two 
possible amino acid residues present at each of them, leucine and arginine in position 
133 and valine and methionine in position 142. Of these, Leu-133 and Met-142 appeared 
to confer risk to the disease (p=4.79E-10, OR=1.94). Interestingly, these amino acids 
correlated with two other residues of the HLA-DRβ molecule, proline in position 11 and 
arginine in position 13 (Table 2). Therefore, the conditional analysis adjusting for each 
of the amino acid residues (Leu-133, Met-142, Pro-11 or Arg-13) could not statistically 
distinguish which of them was driving the effect. 
Finally, functional annotation analysis indicated that most of the SNPs linked to the HLA-
DRA gene (including the SNP with the strongest association, rs7197) have a regulatory 
role in immune cell lines, modulating the expression of a large number of genes, 
including DRB1 and DQB1 (Supplementary Table 8). 
 
Non-HLA associations 
Outside the HLA region, a novel signal was observed in chromosome 2q11.2 (Figure 1). 
The rs7608679 genetic variant, located in an intergenic region between the MAP4K4 
(mitogen-activated protein kinase kinase kinase kinase 4) and IL1R2 (interleukin 1 
receptor type 2) genes, reached the established significance threshold in the meta-
analysis (p=8.38E-07, OR=1.42) (Table 3). In addition, several other genetic variants in 
tight LD with it also showed strong associations. However, stepwise logistic regression 
analyses, conditioned on the most highly associated polymorphism, showed there were 
no other variants with independent effects (Figure 4). 
When we evaluated the potential regulatory role of rs7608679 and its proxies, several 
SNPs (rs13011687, rs12473090, rs12990046 and rs1541435) overlapped with histone 
marks enriched at promoters and enhancers in different immune cell lines (monocytes, 
neutrophils and primary B cells) (Table 4). Furthermore, all of them appeared to influence 
the expression levels of both the IL1R2 and the MAP4K4 genes in whole blood.  
Finally, we also evaluated signals reaching our suggestive tier of association (2.29x10-
5). Genetic variants in five genetic regions passed this statistical threshold (Figure 1 and 
Table 3). The third strongest signal belonged to a SNP (rs76649453) in an intronic region 
of the KIAA1109 locus (p=4.07E-06, OR=2.31). This gene is located within a large 
haplotype block encompassing the autoimmunity-associated genes IL2 and IL21. 
Suggestive associations were also found for SNPs in close proximity to RCL1/JAK2 
(RNA terminal phosphate cyclase like 1/janus kinase 2) (rs7862852: p=8.82E-06, 
OR=1.35), CASP10/TRAK2 (caspase 10/trafficking kinesin protein 2) (rs17672977: 
p=1.02E-05, OR=2.07), ERC2 (ELKS/RAB6-interacting/CAST family member 2) 
(rs13098621: p=1.23E-05, OR=1.50) and HHEX/EXOC6 (hematopoietically expressed 
homeobox/exocyst complex component 6) (rs11187157: p=1.96E-05, OR=1.33). 
For all these loci, except for ERC2, the top associated SNPs, or those showing high LD 
with them (r2> 0.8), seemed to have potential functional roles (Table 4). Enrichment for 
histone marks, Dnase hypersensitive sites and/or eQTLs were evident using publicly 
available functional annotation data. Interestingly, the lead SNP within the HHEX/EXOC6 
region influenced gene expression levels of EXOC6 and KIF11 (kinesin family member 
11). Regarding CASP10/TRAK2, several proxy SNPs correlated with the expression of 
two genes located in the same haplotype block, CFLAR (CASP8 and FADD like 
apoptosis regulator) and PPIL3 (peptidylprolyl isomerase like 3). Finally, the associated 
SNP within the RCL1/JAK2 locus was highly correlated with the expression of JAK2 in 
whole blood. 
 
 
 
DISCUSSION 
By conducting the first large-scale genotyping study in non-infectious uveitis, we have 
confirmed the HLA locus as the most strongly associated region with this inflammatory 
condition. We have explored subphenotype associations, both shedding light into the 
previously reported HLA signals and identifying possible mechanisms by which these 
molecules are involved in the development of uveitis. Furthermore, outside the HLA 
region, we have detected a new risk locus, MAP4K4/IL1R2, and five suggestive 
associations with KIAA1109, RCL1/JAK2, CASP10/TRAK2, ERC2 and HHEX/EXOC6. 
The correlation between BSCR and the classical allele HLA-A*2902 represents one of 
the strongest associations between the HLA region and disease reported to date33. In 
this regard, our results suggest that this effect could be driven by the amino acid 
Leu62/Gln63. Indeed, in our study cohort, both residues, Leu62 and Gln63, are specific 
to the classical alleles HLA-A*2902 and *2901. The lack of association between HLA-
A*2901 and BSCR in our dataset (p=0.201) was probably due to the lower frequency of 
this classical allele (0.002) compared with HLA-A*2902 (0.057). Indeed, a nominal 
association between HLA-A*2901 and BSCR was reported in a previous GWAS20, in 
which the relative effect sizes for these classical alleles were entirely consistent with our 
data. It should be noted that the amino acid positions 62 and 63 of the HLA-A protein are 
likely to be involved in the antigen presentation process. On one hand, the position 62 
within the antigen binding site is positioned to make direct contact with the T cell 
receptor36, whereas the position 63 faces into the antigen binding site and is likely to be 
involved in peptide binding36, 37. Therefore, these amino acid positions could be 
responsible for the effect of the HLA-A molecule on the BSCR susceptibility. 
Our study confirms the previously reported association between the HLA-DR15 
haplotype and idiopathic intermediate uveitis34, 35. Interestingly, this haplotype represents 
the primary HLA genetic susceptibility factor for multiple sclerosis (MS) 38, an immune-
mediated disease often associated with intermediate uveitis 39. However, our data 
revealed that the classical alleles forming this haplotype (DRB1*1501, DQA1*0102 and 
DQB1*0602) have an even stronger influence on susceptibility to posterior uveitis 
compared with the intermediate form of the disease. The combined analysis of both 
intermediate and posterior uveitis patients pointed toward positions 133 and 142 of the 
HLA-DRβ1 molecule as the most relevant for disease susceptibility. None of these 
positions have been reported to be involved in antigen presentation; however, amino 
acid residues conferring risk to the disease (Leu-133 and Met-142) were almost 
completely linked to Pro-11 and Arg-13. Both proxy positions lie within the peptide 
binding groove of the HLA-DR molecule and therefore, a functional role can be more 
reliably ascribed to them. Indeed, these same amino acid positions have been reported 
to be the most relevant for systemic lupus erythematosus susceptibility40. Additionally, a 
previous fine-mapping of the HLA region in MS identified the position 71 of DRβ1 as the 
most significant conferring risk41. This is also located in the peptide groove of the HLA-
DR molecule and is tightly correlated with positions 11 and 13 (r2=0.90). Indeed, in our 
dataset, the amino acid alanine in position 71 also showed high statistical significance, 
as shown in Supplementary Table 6.  
On the other hand, the highest signals associated to intermediate and posterior uveitis 
belonged to a set of highly linked genetic variants located in the HLA-DRA gene. Many 
of these SNPs appeared to act as eQTLs affecting the expression levels of a number of 
genes, some of which encodes HLA molecules, such as DQB1 and DRB1. Therefore, a 
potential functional effect of these polymorphisms on the pathogenesis of posterior and 
intermediate uveitis cannot be discounted. In this instance, polymorphisms of the HLA 
region in this subgroup of patients could be altering the expression of certain genes 
rather than directly influencing the antigen presentation process. Nevertheless, the high 
LD between the associated SNPs, classical alleles and amino acid residues makes it 
difficult to determine the true causal variant.  
Outside the HLA region, we identified the MAP4K4/IL1R2 locus as a new genetic risk 
factor for non-infectious non-anterior uveitis. In silico eQTL analysis showed several 
proxy SNPs affecting the expression levels of these two genes in whole blood. MAP4K4 
encodes a member of the serine/threonine protein kinase family, which is involved in the 
tumour necrosis factor-alpha (TNF-α) signalling pathway, whereas IL1R2 encodes a 
cytokine receptor that inhibits the activity of its ligands (IL-1A, IL-1B and IL1R1). Both 
proinflammatory cytokines, TNF-α and IL-1, have been detected in the eye during active 
inflammation42. Interestingly, two recent clinical trials have demonstrated an effective 
response to adalimumab treatment, a TNF-α inhibitor, in patients with non-infectious 
intermediate, posterior, or panuveitis 43, 44. Similarly, treatment with gevokizumab, a 
monoclonal antibody inhibiting the activation of IL-1 receptors, has also shown 
therapeutic efficacy in patients with Behçet’s disease uveitis 45. Moreover, this region has 
been previously associated with ankylosing spondylitis (AS)46, an inflammatory disorder 
that frequently presents acute anterior uveitis (30-40% of AS patients).  
Evidence for eQTLs was found for three of the five loci showing suggestive associations 
with uveitis and may help annotate these signals. In this regard, the association observed 
in the HHEX/EXOC6 region seemed to be due to an eQTL influencing the expression of 
EXOC6 and KIF11. EXOC6 is one of three genes included in a chromosomal 
microdeletion leading to an autosomal dominant form of non-syndromic optic nerve 
aplasia47; whereas mutations in KIF11 cause an autosomal dominant disorder 
characterised by chorioretinopathy48. SNPs within the CASP10/TRAK2 locus were found 
to affect the expression of two genes located in the same haplotype block; CFLAR, a 
regulator of apoptosis, and PPIL3, involved in protein folding. Finally, eQTL analysis 
showed that JAK2 was the most likely causal gene within the RCL1/JAK2 locus. JAK2 
encodes a signal transducer that plays an important role in the differentiation of Th1 and 
Th17 lymphocytes and both cell types are heavily implicated in the pathogenesis of 
autoimmune uveitis 49. 
In summary, our study has revealed new associations with non-infectious uveitis, both 
within and outside the HLA region. The identification of genetic risk factors influencing 
this disorder will further elucidate the complex mechanisms underlying uveitic conditions. 
Further studies in larger cohorts will be desirable in order to confirm the detected signals. 
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Table 1. Amino acid residues of the HLA-A molecule showing the strongest associations with birdshot chorioretinopathy. 
   Residue frequency Meta-analysis Spain Netherlands 
Amino acid 
residue 
Binding 
Pocket 
Classical 
HLA Alleles 
Birdshot Controls P-value OR [95% CI] P-value OR [95% CI] P-value OR [95% CI] 
Leu62 Yes 
*29:01 and 
*2902 
0.519 0.059 5.33E-35 49.48 [26.63-91.93] 3.22E-21 25.56 [13.05-50.03] 1.08E-12 219.20 [49.72-966.80] 
Gln63 Yes 
OR, odds ratio; CI, confidence interval. 
 
 
 
 
 
 
 
 
Table 2. Amino acid residues of the HLA-DRβ1 molecule showing the strongest associations with intermediate and posterior uveitis.  
 
    Residue 
frequency 
Meta-analysis Spain Netherlands UK 
Amino acid 
residue 
Binding 
pocket 
r2 with Pro11 
Classical HLA 
alleles 
IU+PU Controls P-value OR [95% CI] P-value OR [95% CI] P-value OR [95% CI] P-value OR [95% CI] 
Pro11 Yes NA 
15:01, 15:02 
and 15:03 
0.210 0.131 4.43E-10 1.94 [1.58-2.40] 5.12E-09 2.26 [1.72-2.98] 0.091 1.53 [0.93-2.49] 0.015 1.75 [1.12-2.75] 
Arg13 Yes 1 0.210 0.131 4.43E-10 1.94 [1.58-2.40] 5.12E-09 2.26 [1.72-2.98] 0.091 1.53 [0.93-2.49] 0.015 1.75 [1.12-2.75] 
Leu133 No 0.995 0.210 0.132 4.79E-10 1.94 [1.58-2.39] 5.55E-09 2.26 [1.72-2.97] 0.090 1.53 [0.94-2.49] 0.016 1.74 [1.11-2.74] 
Met142 No 0.995 0.210 0.132 4.79E-10 1.94 [1.58-2.39] 5.55E-09 2.26 [1.72-2.97] 0.090 1.53 [0.94-2.49] 0.016 1.74 [1.11-2.74] 
NA, not applicable; OR, odds ratio; CI, confidence interval; IU, intermediate uveitis; PU, posterior uveitis. 
 
Table 3. Non-HLA loci associated with non-infectious non-anterior uveitis at the established significance level (p<1.14×10−6) (bold) and at the 
suggestive significance level (p<2.29×10−5). 
     Allele frequency   
    Spain Netherlands UK Meta-analysis 
Chromosome Loci Most significant SNP Minor allele Uveitis Controls Uveitis Controls Uveitis Controls P-value OR [95% CI] 
2 MAP4K4 / IL1R2 rs7608679 C 0.301 0.234 0.357 0.240 0.277 0.246 8.38E-07 1.42 
4 KIAA1109 rs76649453 A 0.047 0.018 0.040 0.020 0.027 0.015 4.07E-06 2.31 
9 RCL1/JAK2 rs7862852 C 0.388 0.327 0.401 0.375 0.464 0.346 8.82E-06 1.35 
2 CASP10/TRAK2 rs17672977 G 0.033 0.020 0.075 0.033 0.055 0.024 1.02E-05 2.07 
3 ERC2 rs13098621 A 0.160 0.108 0.147 0.102 0.150 0.115 1.23E-05 1.50 
10 HHEX/EXOC6 rs11187157 C 0.442 0.388 0.528 0.445 0.509 0.448 1.96E-05 1.33 
OR, odds ratio; CI, confidence interval. 
 
Table 4. Functional annotation for the non-HLA genetic variants showing associations (p<1.14x10-6) or suggestive associations (p<2.29x10-5) 
with non-infectious non-anterior uveitis. The most highly associated polymorphisms and those in tight linkage disequilibrium with them (r2>0.8) 
were used for the analysis. 
 
Mapped genes Lead SNP Location eQTL Promoter histone marks Enhancer histone marks Dnase hypersensitivity 
MAP4K4 / IL1R2 rs7608679 Intergenic IL1R2, MAP4K4 Yes Yes No 
KIAA1109 rs76649453 Intronic - Yes Yes No 
RCL1 / JAK2 rs7862852 Intergenic JAK2 Yes Yes No 
CASP10/TRAK2  rs17672977 Intronic PPIL3, CFLAR Yes Yes Yes 
ERC2 rs13098621 Intronic - No No No 
HHEX/EXOC6 rs11187157 Intergenic EXOC6, KIF11 Yes Yes Yes 
eQTL, expression quantitative trait loci; SNP, single nucleotide polymorphism. 
FIGURE LEGENDS 
Figure 1. Manhattan plot of the meta-analysis of the three analysed cohorts. The red 
and blue lines represent the established (p=1.14×10−6) and the suggestive (p=2.29×10−5) 
significance levels, respectively.  
 
Figure 2. Manhattan plot representing the results of the conditional logistic regression 
analysis of the HLA region in patients with birdshot chorioretinopathy. (A) Unconditioned 
test of the HLA region. (B) Results after conditioning on the HLA-A*2902 classical allele. 
(C) Results after conditioning on the amino acid residue Leu62/Gln63. The red/green 
color gradient represents the effect direction of each analyzed variant (red for risk and 
green for protection). The size of the diamonds indicates the degree of linkage 
disequilibrium with the classical allele HLA-A*2902. The red line represents the 
established significance threshold (p<1.14x10-6). 
 
Figure 3. Manhattan plot representing the results of the conditional logistic regression 
analysis of the HLA region in patients with posterior and intermediate uveitis. (A) 
Unconditioned test of the HLA region. (B) Results after conditioning on the rs7197 
polymorphism. (C) Results after conditioning on the HLA-DRB1*1501 classical allele. 
The red/green color gradient represents the effect direction of each analyzed variant (red 
for risk and green for protection). The size of the diamonds indicates the degree of 
linkage disequilibrium with the classical allele HLA-DRB1*1501. The red line represents 
the established significance threshold(p<1.14x10-6). 
 
Figure 4. Regional plot of the non-HLA locus associated with non-infectious non-anterior 
uveitis in the meta-analysis. (A) Unconditioned analysis. (B) Results after conditioning 
on the lead SNP (rs7608679). 
 
